Tus kws kho mob
P9-17 A New Drug, Ingrezza (valbenazine) Will Require Prior Authorization
Hnub Tim pib siv tau lub khoos kas: Lub Peb Hlis Ntuj Tim 21, 2017
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 2591 - 2600 ntawm 4269
Tus kws kho mob
P48-17 EquiClaim to Perform Focused and Limited Hospital Bill Validation Services
Hnub Tim pib siv tau lub khoos kas: Lub Cuaj Hlis Ntuj Tim 19, 2017
Tus kws kho mob
P21-17 New Drug-Related Prior Authorization with Quantity Limit for Entresto
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 08, 2017
Tus kws kho mob
P45-17 New Drug-Related Prior Authorization and Quantity Limit Criteria: Concurrent Opioids with Buprenorphine
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 14, 2017
Tus kws kho mob
P13-17 Added Reimbursement Policy for General Coding: Total Parenteral Nutrition Billing
Hnub Tim pib siv tau lub khoos kas: Lub Plaub Hlis Ntuj Tim 07, 2017
Tus kws kho mob
P42-17 Addition of Drugs to Self-Administered Oncology Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 03, 2017
Tus kws kho mob
P77-17 Medicare Advantage Process for NOMNC Letter
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 12, 2017
Tus kws kho mob
P44-17 New Drug-Related Prior Authorization and Quantity Limit Criteria: Opioid, Buprenorphine Concurrent Therapy
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 14, 2017
Tus kws kho mob
P16-17 Changes in Medical Policy IV-107 Hip Arthroplasty (Hip Replacement) and Hip Resurfacing
Hnub Tim pib siv tau lub khoos kas: Lub Plaub Hlis Ntuj Tim 28, 2017
Tus kws kho mob
P34-18 Clarification to MAPD PA Requirements for Hereditary Angioedema (HAE) Medical Drugs
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 01, 2018